A class of drugs called fibrates, commonly referred to as fibric acid derivatives, is used to treat lipid diseases, particularly hypertriglyceridemia and mixed dyslipidemia. These medications, along with statins and other lipid-lowering medications, have become a crucial part of the pharmacological toolbox for treating a variety of lipid-related diseases. Fibrates work therapeutically by concentrating on nuclear receptors called peroxisome proliferator-activated receptors alpha (PPAR-), which are mostly present in the liver, muscles, and adipose tissue. A series of biochemical processes initiated by PPAR-activation ultimately result in the upregulation of genes involved in lipid metabolism. The stimulation of lipoprotein lipase, an enzyme that breaks down triglycerides in circulating lipoproteins, is one of fibrates' most notable effects. As a result, the plasma triglyceride levels drop, which is a sign of hypertriglyceridemia. Fibrillates have modestly positive effects on high-density lipoprotein cholesterol (HDL-C) levels in addition to reducing triglyceride levels, which is commonly referred to as "good cholesterol." Fibrillates can raise HDL-C levels and enhance the lipid profile by increasing the synthesis of HDL particles and encouraging their maturation. Additionally, it has been demonstrated that fibrates lower levels of tiny, dense LDL particles, which are more atherogenic and linked to a higher risk of cardiovascular disease. Fibrillates have shown potential cardiovascular advantages in addition to their lipid-modifying capabilities. Fibrates may lower the risk of cardiovascular events, particularly in people with hypertriglyceridemia, according to several clinical trials. They may also be helpful for people who have mixed dyslipidemia, a major metabolic risk factor for heart disease marked by increased triglycerides and low HDL-C. The care of lipid diseases, particularly hypertriglyceridemia and mixed dyslipidemia, depends heavily on fibrates. They are an important addition to the therapy options available to patients with dyslipidemia due to their capacity to lower triglycerides, increase HDL-C levels, and possibly lessen the risk of cardiovascular events. However, before including fibrates in a patient's lipid-lowering therapy, medical professionals must carefully analyze each patient's unique risk factors, prescription interactions, and potential adverse effects.